Good Deed Of The Day: Mentor Capital Pledges $125 Million for Direct Cancer Equity Funding (MNTR)

Mentor Capital (MNTR) announced the launch of its $125 Million Direct Cancer Equity Funding Program. “Our shareholders have told us they want their purchase of Mentor stock to fund the development of leading-edge cancer solutions,” reports CEO, Chester Billingsley. “Trading cancer shares can be profitable, but socially responsible investing is best served by injecting funds directly.” Mentor's Direct Cancer Equity Funding Program was created to translate an investor share purchase into cash funding for cancer breakthroughs. The Mentor Capital securities structure is 93% warrants with only 2 million shares outstanding. As a result, asset accumulation and share purchases will strongly influence the exercise of Mentor's $125 Million in warrants. Cancer development firms needing funding will be screened to approximately fifteen that may each deposit $5 -$15 Million of their restricted securities in a $125 Million Mentor Cancer Equity Funding Portfolio. Net funds from a following exercise of Mentor warrants are then paid out pro rata to portfolio companies. None of a participating company's shares may be sold, loaned, voted or released until all of that company's investment receivable is retired in cash. Preliminary discussions have been fruitful. Indications are that after the non-profit phase cancer development is often financially underserved. Further, biotech firms typically need approximately $10 Million to move through an early stage of FDA trials. That amount seems to well match Mentor's funding structure. A principal advantage of Mentor Capital in selecting firms to fund continues to be the expertise of its management in screening the medical science of complex cancer therapies. This management insight helps ensure that new and existing shareholder purchases are focused along the lines of the socially responsible investment and benefit that Mentor Capital shareholders desire.